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Poster Session I S291complete remission (CR) rates and long-term survival, however, it
remains associated with significant treatment related mortality
(TRM) and it remains unclear whether aCT - orTBI-basedMA reg-
imen is most efficacious. RIC has also been shown to achieve durable
long-term survival with a lower TRM (15-25%) and has been gener-
ally used for older patients. To attempt to compare these procedures
an analysis of CLL patients undergoing first Human Leukocyte An-
tigen (HLA)-matched sibling donor (MRD)HCTbetween 1995 and
2007was performed, focusing on differences between: 1)MA vs. RIC
transplants; and 2) CT- vs. TBI-based MA conditioning.
Among 297 patients, 163 MA vs. 134 RIC, significant differences
in baseline characteristics included:Median age; source of stem cells;
median donor age; use of antithymocyte globulin (ATG); graft ver-
sus host disease (GVHD) prophylaxis; and the year of transplanta-
tion. Multivariate analysis demonstrated that MA conditioning was
associated with a higher incidence of acute GVHD (p 5 0.002)
and a higher TRM (p 5 0.003), but a lower relapse rate (p 5
0.005). Although there was no difference in survival before year
2000, after year 2000, MA conditioning was associated with reduced
survival by almost 2-fold (p 5 0.019).
Among 163 patients who had MA conditioning, 110 were TBI-
based and 53 were CT-based. Significant differences in baseline
characteristics were: Rai stage at diagnosis, stem cells source, and
the use of ATG (0 vs. 11%, p\0.001). As compared to the CT-based
transplants those with TBI tended to be performed earlier with the
majority being before year 2000 (p 5 0.052). Although there were
no significant differences between the groups regarding GVHD,
neutrophil engraftment, relapse or survival, the CT-based condi-
tioning group had higher TRM (p 5 0.006) and treatment failure
risk.
We conclude from this large retrospective comparison that RIC
HCT from a MRD is effective in an older CLL population with su-
perior survival and less TRM than that observed withMA condition-
ing. However, due to the higher relapse rate in the RIC group, future
strategies to enhance the anti-leukemic effect are warranted. In the
MA setting, TBI-based conditioning may be superior to a CT-based
approach; however, recognizing the emerging efficacy of RICHCT,
a prospective comparison is unlikely to be performed.234
PRECLINICAL MODEL TO PREDICT ANTI-LEUKEMIC ACTIVITY OF
BUSULFAN AND IRRADIATION
Patel, P.R.1, Mahmud, D.1, Zhan, W.2, Zhou, T.2, Weichselbaum, R.R.3,
Garcia, J.G.N.2, Rondelli, D.1 1University of Illinois at Chicago; 2Uni-
versity of Chicago; 3University of Chicago
We tested the in vitro effect of physiologic doses of busulfan (Bu)
and ionizing radiation (IR) to address whether additive antileukemic
activity can be demonstrated in two leukemic cell lines, one sensitive
(HL60) and one resistant (K562) to radiation. Cells were treated for
24 hours with Bu doses ranging from at 0 to 200 mg/ml, or IR at 1.5, 3
or 6 Gy, or with BU at 12.5 or 25 mg/ml for 24 hours, followed by IR
at 1.5 or 3Gy. Cells were then tested for proliferation, expression of
annexin-V and caspase-3, and colony formation. Exposure to Bu or
IR induced a variable but dose dependent inhibition of proliferation
and colony formation in HLA-60 cells. On the contrary, we could
observe a significant cytotoxic effect in K562 cells by using IR at 6,
but not 1.5 or 3.0 Gy (p5 0.008). In addition, treatment with either
Bu or IR caused apoptosis with increased caspase-3 expression in
HL60 cells, but not in K562 cells. To test a possible synergistic effect
of the combination of Bu and IR, we treated the cells with Bu for 24
hours followed by radiation. HL60 cells were strongly inhibited by
both agents when separate or combined. In contrast, treatment of
K562 cells with low dose IR (3Gy) alone inhibited colony formation
by 28% and with low dose Bu by 77%. The inhibitory effect of low
dose Bu + IR 3Gy increased up to 86%, suggesting that Bu could in-
duce radio-resistant leukemic cells to become more radio-sensitive.
In order to identify genes associated with a response to Bu, we
formed a linear regression model controlled for cancer type using
GI50 and Stanford cDNA array data from the NCI-60. 7 genes
were identified that strongly correlated with response (p\0.001
and FDR 50%). The most significant genes were then tested in
the Affymetric U133 plus 2.0 platform. Our analysis identified sixgenes (ERC2, HCLS1, CD74, KCNH2, HLADQB2, CD53) which
are significantly associated with response to Bu (p\0.05). Our in-
vitro study demonstrated an additive effect of Bu and low dose IR
even on radioresistant leukemic cells. The identification of a genomic
signature for response to Bu validated by in vitro functional assays
represents a novel approach for a personalized chemo-radiotherapy
in patients with AML undergoing an allogeneic stem cell transplant.235
TARGETING LEUKEMIA BY CD123 SPECIFIC CHIMERIC ANTIGEN
RECEPTOR
Thokala, R., Olivares, S., Singh, H., Champlin, R.E., Cooper, L.J.N.MD
Anderson Cancer Center, Houston, TX
Chimeric antigen receptors (CARs) are employed to genetically
modify T cells to redirect their specificity to target antigens on tu-
mor cells. Typically a second generation CAR is derived by fusing
an extracellular domain derived from the scFv of monoclonal anti-
body (CAR) specific to targeted antigen with CD3z, and CD28 en-
dodomains. CD123 (IL3RA) is expressed on 45% to 95% of acute
myelogenous leukemia (AML) and B-cell lineage acute lymphoblas-
tic leukemia (B-ALL). Expression of CD123 is high in the leukemic
stem cell (LSC) population, but not in normal hematopoietic stem
cells. Thus, CD123 appears to be potential target for immunother-
apy in leukemias through chimeric antigen receptor (CAR). We hy-
pothesized that the generation of CD123 specific CAR can redirect
the specificity of T cells to CD123 and this was tested by cloning the
scFv of CD123mAb in our CAR construct. The sleeping beauty sys-
tem was used to express the CAR and DNA plasmids were electro-
porated into peripheral blood mononuclear cells and cells were
numerically expanded on artificial antigen presenting cells geneti-
cally modified to express co stimulatory molecules CD86, 4-1BBL,
membrane-bound IL-15, and CD123 antigen in presence of IL-21
and 1L-2. CAR+T numerically expanded to clinically relevant num-
bers and showed antigen specific cytotoxicity in leukemic celllines.
CAR+ T cells expressed both effector and memory markers showing
the potential for in vivo persistence after T cell infusion. The bone-
marrow homing receptor CXCR4 was expressed by CAR T cells
shows the potential to target LSC that reside in BM niches. The pre-
liminary data suggests that mirroring an approach we are using to
manufacture clinical grade CD19 specific CAR+ T cells.236
INCREASED ABILITY TO TRANSPLANT AND IMPROVED SURVIVAL IN
PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA (AML) AFTER
INDUCTION WITH HIGH DOSE CYTARABINE AND MITOXANTRONE
(HIDAC/MITO)
Ramanathan,M., Cerny, J., Raffel, G., Petrillo-Deluca, L., Tarrasky, N.,
Nath, R. UMass Memorial Medical Center, Worcester, MA
Background: Patients with high risk AML have a poor prognosis
and inferior outcomes after 7+3 induction. Complete remission
(CR) rates range from 6-51% and induction death rates between
9-48%. We present a single institution experience in high risk
AML patients treated with HIDAC/MITO induction regimen
(Blood 2010; 116: 3290).
Methods: We have retrospectively analyzed the outcome of 43 pa-
tients with AML who received HiDAC/MITO induction at our in-
stitution from January 2009- September 2011. High risk features
included at least one of the following such as age.60, high risk cy-
togenetics, high age adjusted Charlson comorbidity index (CCI)
and non denovo AML (therapy related, antecedent hematological
disorder or relapsed AML). The endpoints analysed were CR (mar-
row blasts\5%) at day 30, induction mortality within 30 days of in-
duction, ability to proceed to transplant, number of days to
transplant, overall survival (OS) and progression free survival
(PFS) of transplanted vs non transplanted patients, calculated from
day 1 of induction.
Patient characteristics:Themedian age was 67 years (47 - 83), me-
dian age adjusted CCI was 6 (4 -12), 26 (60%) were males and 17
S292 Poster Session I(40%) were females. 23 (53.5%) had high risk cytogenetics and 19
(44%) had non-denovo AML. There was no statistically significant
difference in cytogentic risk (p 5 0.56) or diagnosis of non denovo
AML (p 5 0.18) between the transplant and the non transplant
groups.
Outcomes: CR rate including CR without platelet recovery (CRp)
was 88 % with no induction related deaths. Of the 38 patients who
went into remission 7 (18%) relapsed at a later time point. Median
follow up of the entire cohort was 181days (24 to 987). 20 (47%) pa-
tients were able to proceed to transplant, 6 underwent autologous
SCT, 12 underwent allogeneic SCT and 2 underwent autologous
SCT followed by an allogeneic SCT at relapse. The median time
to first SCT since induction was 115 days (32 - 195). Median OS
was 11.3 months. Median OS of the patients who underwent SCT
is *not reached vs 5.1 months for the non transplant group (p 5
0.0055). Median PFS of patients who underwent SCT was *not
reached vs 5.9 months for the non transplant group, (p 5 0.0229).
Conclusions: In this high risk AML population, HiDAC/MITO in-
duction was well tolerated and demonstrated an excellent CR/CRp
rate of 88% with no induction deaths. Substantial number (47%)
of patients proceeded to SCT and had a significantly better outcome
(both OS and PFS).237
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) IN THE
ELDERLY PATIENTS (AGE . 65 YEARS) WITH ACUTE MYELOID
LEUKEMIA (AML) IS SAFE AND EFFECTIVE
Jagadeesh, D.1,2, Cerny, J.1,2, Ramanathan, M.1,2, Raffel, G.D.1,2,
Petrillo-Deluca, L.2, Tarrasky, N.2, Krumpe, L.M.2, Bednarik, J.2,
Barton, B.A.1, Walsh, W.V.1,2, Nath, R.1,2 1Univeristy of Massachusetts
Medical School, Worcester, MA; 2UMass Memorial Medical Center,
Worcerster, MA
Introduction: AML patients over age 65 years have a poor outcome
with a median survival of 2 months and a 2-year survival rate of 6%
(Menzin et al Arch Intern Med. 2002). Allo-SCT is curative in AML
but is frequently not offered to older patients because of the concern
of high mortality associated with this procedure.
Methods: Retrospective analysis was performed on all patients with
AML over age 65 years who underwent an allo-SCT at UMass Me-
morial Medical Center since 2009. The study was approved by
UMass Memorial Medical Center IRB.
Results: 9 patients were identified from the database. There were 6
men and 3 women. Median age at SCT was 69 years range (65-78). 4
patients were$70 years of age. Disease status at SCT was complete
remission (CR) in 4 (44%) and persistent disease in 5 (56%) patients.
Median number of chemotherapy cycles prior to SCT was 3 range
(1-14). 1 patient had 2 prior autologous SCT. 5 (55%) patients
had poor prognostic cytogenetics (including Flt-3 ITD) and 6
(67%) patients had preceding MDS. Median time from diagnosis
to SCT was 197 days range (105-2240). Stem cell source was single
cord blood (CB) unit in 3 and unrelated donor in 6 patients. Prepar-
ative regimen was myeloablative in 4 (Thiotepa10mg/kg/Flu/Mel
140mg/m2/rabbitATG in 3 CB-SCT; Flu/Bu3.2mg/kg x 3/ATG
in 1) and reduced intensity in 5 patients (Flu/Bu3.2mg/kg x 2/
ATG). Graft versus host disease (gvhd) prophylaxis was tacroli-
mus/mycophenolate mofetil (MMF) in 6 and sirolimus/MMF in 3
subjects.Median number of stem cell infusedwas 4.99 x106 /kg range
(1.7 x105- 6.14 x106). All 9 patients engrafted with full donor chime-
rism and were in CR post SCT.Median time for neutrophil engraft-
ment was 18 days range (13-41) and platelet engraftment was 13 days
range (11-73). Grade II-IV acute gvhd developed in 2 patients. Day
100 survival was 8/9 (89%). The Kaplan-Meier Product-Limit esti-
mates show that the long-term survival probability is 0.78 and is sta-
ble at that level after 6 months. Four patients have survival times
longer than one year with two patients surviving beyond two years.
No patient relapsed post SCT. All surviving patients have Karnofsky
performance score $80. 2 patients are off all immunosuppressant
therapy.
Conclusion: Allogeneic SCT is safe and effective treatment modal-
ity for elderly AML patients. This treatment modality needs to be
validated in prospective clinical trials.238
EFFECT OF PRE-TRANSPLANT CHEMOTHERAPY BEFORE HUMAN
LEUKOCYTE ANTIGEN IDENTICAL SIBLING TRANSPLANTATION FOR
ACUTE MYELOGENOUS LEUKEMIA IN FIRST COMPLETE REMISSION
Ghavamzadeh, A., Hoghooghi, M., Jahani, M., Alimoghaddam, K.,
Mousavi, S.A., Bahar, B., Iravani, M., Jalili, M., Jalali, A. Tehran Uni-
versity of Medical Sciences, Tehran, Islamic Republic of Iran
Background: Pre-transplant consolidation therapy for patients with
AML in the first complete remission (CR) decreases leukemia recur-
rence and improves survival.
Patients and Methods: 29 AML patients (15 females and 14 males)
with a median age of 33 years (range 18-63) enrolled from Feb. 2010
to Oct. 2011 were randomly allocated into two groups. 14 patients in
the first group (A) received 7+3 chemotherapy regimen (cytarabine
100mg/m2/day for 7 days+ idarubicin 12mg/m2/day for 3 days) prior
to hematopoietic stem cell transplantation (HSCT) and 15 patients
in the second group (B) received 7+3 regimen followed by 5+2 (cytar-
abine 100mg/m2/day for 5 days+ idarubicin 12mg/m2 for 2 days) be-
fore HSCT. All Patients were in complete remission before
transplantation. Peripheral blood stem cells were the preferred
source for transplantation.
Results: The median time from diagnosis to transplant was 70.5
days in the B and 171 in the A group. The median time to absolute
neutrophil count $ 0.5*10^9/L was +13 days in the B and + 14
in the A group (p 5 0.18). The median time to platelet count $
20000 was +15 days in the B and +16 in the A group (p5 0.32). Me-
dian follow-up time was 128 days. Acute GVHD occurred in 7
(46.7%) patients in the B and in 11 (78.6%) patients in the A group.
Themost common grade of acute GVHDwas grade II for 3 (42.9%)
and 8 (72.7%) patients in the B and A groups, respectively. At this
time, 24 patients (82.3%) are still alive (13 in the B & 11 in the A
group). The causes of death were GVHD in 3 patients (1 in the B
and 2 in the A group), relapse (1 patient in the B group) and CMV
infection (1 patient in the A group). 4-month overall survival was
92.3% (SE: 7.4%) and 80% (SE: 12.6%) in the B and A groups, re-
spectively (p5 0.4). 4-monthLeukemia-free survival was 82.1% (SE:
11.7%) in the B and 80% (SE: 12.6%) in the A group (p 5 0.64).
The cumulative incidence of acute GVHD on +12 days was 20%
(95% C.I.: 5%-43%) in the B and 64% (95% C.I.: 32%-84%) in the
A group that was statistically significant (p 5 0.032).
Conclusion: Preliminary results show that omitting consolidation
therapy prior to hematopoietic stem cell transplantation has no ad-
verse impact on survival outcome in short-term follow-up of pa-
tients, but reduces the cumulative incidence of acute GVHD after
transplantation. More cases and longer duration of follow-ups are
needed to achieve significant results.239
STEM CELL TRANSPLANT (SCT) OVERCOMES THE POOR PROGNOSIS AS-
SOCIATED WITH CD25 EXPRESSION IN ACUTE MYELOID LEUKEMIA
(AML): ARETROSPECTIVE SINGLE CENTER ANALYSIS
Cerny, J.1, Ramanathan, M.1, Yu, H.1, Raffel, G.D.2, Walsh, W.V.1,
Petrillo-Deluca, L.J.1, Tarrasky, N.1, O’Rourke, E.1, Bednarik, J.1,
Hao, S.2, Hutchinson, L.2, Woda, B.2, Barton, B.3, Rosmarin, A.G.1,
Nath, R.1 1University of Massachusetts Medical School, Worcester, MA;
2University of Massachusetts Medical School, Worcester, MA; 3University
of Massachusetts Medical School, Worcester, MA
We have recently identified that expression of CD25 on leukemic
blasts as a novel prognostic marker associated with high relapse rate
and short relapse free survival (RFS). CD25+ was a more robust pre-
dictor of AML relapse (multivariate Cox regression analysis HR 6.54
[1.34-9.15], p 5 0.01; FLT3-ITDmut: HR 4.72 [2.04-10.92], p 5
0.03). CD25+ leukemic cells resembled behavior of leukemic stem
cells (LSCs) as described by Saito et al (Sci Transl Med 2010). We
report the effect of stem cell transplantation (SCT) on outcome of
pts with CD25+ AML.
We retrospectively examined the impact of SCT in 46 AML pa-
tients eligible for induction therapy (excluding APL) in whom
CD25 was assessed.
Median age was 61 years (range, 22-84); 19 were (41%) female.
CD25 was detected in 17 pts (37%). No difference was seen in the
following factors: gender, age, cytogenetics, or presence of
